Ernexa Therapeutics (ERNAW) Total Liabilities (2010 - 2026)

Ernexa Therapeutics has reported Total Liabilities for 17 years, with the latest figure at $3.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 66.54% year-over-year to $3.7 million; the trailing twelve-month figure through Mar 2026 stood at $3.7 million (down 66.54% YoY), and the FY2025 full-year result was $3.4 million, down 3.78% from the prior year.
• Total Liabilities for Q1 2026 stood at $3.7 million, up from $3.4 million in the prior quarter.
• The five-year high for Total Liabilities was $55.0 million in Q2 2024, with the low at $2.6 million in Q3 2025.
• Historically, Total Liabilities has averaged $22.8 million across 5 years, with a median of $12.1 million in 2022.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 586.71% — and 2025, when it plunged 95.1%.
• Ernexa Therapeutics' Total Liabilities stood at $10.2 million in 2022, then jumped by 361.06% to $46.9 million in 2023, then plunged by 92.39% to $3.6 million in 2024, then slipped by 3.78% to $3.4 million in 2025, then climbed by 7.31% to $3.7 million in 2026.
• The last three Total Liabilities figures came in at $3.7 million (Q1 2026), $3.4 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.